AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35751748 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID(+) athletes underwent additional exercise testing, echocardiography and cardiac magnetic resonance imaging (CMR)
Number of subjects: 950
Study 35751748 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-Cov-2 testing, ECG and biomarker profiling (D-Dimer, troponin, C-reactive protein)
Number of subjects: 950
Study 35752023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parent sips, late peer/parent whole drinks
Number of subjects: 1813
Study 35752023 — intervention group
Group type: EXPERIMENTAL
Intervention: Late peer/parent whole drinks
Number of subjects: 1813
Study 35752023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parent sips, mid peer/parent whole drinks
Number of subjects: 1813
Study 35752023 — intervention group
Group type: EXPERIMENTAL
Intervention: Early peer/parent whole drinks
Number of subjects: 1813
Study 35752194 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive children (cases)
Number of subjects: 10997
Study 35752220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative ACE scores
Number of subjects: 798
Study 35752220 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of sexual abuse
Number of subjects: 798
Study 35752220 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depressive thoughts
Number of subjects: 798
Study 35752286 — intervention group
Group type: EXPERIMENTAL
Intervention: rs9914222 variant (associated with plasma FGF21 levels)
Number of subjects: 442
Study 35752286 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of SNHG16 in HepG2 cells
Number of subjects: 442
Study 35752286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol exposure in iPSC-derived brain organoids
Number of subjects: 442
Study 35752286 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma FGF21 levels
Number of subjects: 442
Study 35752539 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-aligned congregate meals and SMBP monitoring
Number of subjects: 94
Study 35752730 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 1102
Study 35752812 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, narrative decision aid video
Number of subjects: 30
Study 35753092 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy and statins adherence
Number of subjects: 307
Study 35753092 — intervention group
Group type: EXPERIMENTAL
Intervention: First year follow-up
Number of subjects: 307
Study 35753092 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque progression
Number of subjects: 307
Study 35753092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during follow-up
Number of subjects: 307
Study 35753512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing, chromosomal microarray, phenotyping, results return with genetic counseling, and reanalysis
Number of subjects: 1505
Study 35754975 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI EEG-based neurofeedback intervention over six weeks
Number of subjects: 5
Study 35754975 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI EEG-based neurofeedback intervention
Number of subjects: 5
Study 35755024 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA International Registry for USAIDs patients
Number of subjects: 290
Study 35756655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab combined with pemetrexed and platinum
Number of subjects: 0
Study 35756842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezabenlimab (anti-PD-1 antibody)
Number of subjects: 0
Study 35756842 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 754111 (anti-LAG-3 antibody)
Number of subjects: 0
Study 35756842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ezabenlimab and BI 754111
Number of subjects: 0
Study 35756843 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib + Immune Checkpoint Blockade (ICB)
Number of subjects: 0
Study 35756843 — intervention group
Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0
Study 35756891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for clinical monitoring of patients prescribed home oxygen therapy
Number of subjects: 0
Study 35757113 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-based tracheostomy education course
Number of subjects: 44
Study 35757113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 35757239 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength training
Number of subjects: 37
Study 35757239 — intervention group
Group type: COMPARATOR
Intervention: Isotonic strength training
Number of subjects: 37
Study 35757242 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary metabolites, particularly polyphenol microbial metabolites
Number of subjects: 160
Study 35757242 — intervention group
Group type: EXPERIMENTAL
Intervention: Various metabolites related to the intake of coffee, red meat, and fish
Number of subjects: 160
Study 35757406 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with morbid obesity
Number of subjects: 0
Study 35757406 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Örebro Musculoskeletal Screening Questionnaire (ÖMSQ-12-TR)
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampa Scale for Kinesiophobia (TSK)
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Numerical Rating Scale (P-NRS)
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal consistency (Cronbach's alpha)
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability (ICC)
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Known-group validity
Number of subjects: 0
Study 35758151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value
Number of subjects: 0
Study 35758267 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan before adherence evaluation
Number of subjects: 319
Study 35758418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 1043
Study 35758418 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily PrEP users)
Number of subjects: 1043
Study 35758424 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect costs associated with pediatric IBD
Number of subjects: 243
Study 35758424 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket (OOP) costs associated with pediatric IBD
Number of subjects: 243
Study 35758424 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel distance to clinic
Number of subjects: 243
Study 35759124 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 10 mg/ml
Number of subjects: 220
Study 35759124 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 40 mg/ml
Number of subjects: 220
Study 35759124 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml
Number of subjects: 220
Study 35759124 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 220
Study 35759134 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP1650 (1000 mg/m)
Number of subjects: 19
Study 35759279 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable electrocardiogram and physical activity sensors
Number of subjects: 20
Study 35759279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with influenza A (H3N2) virus
Number of subjects: 20
Study 35759721 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum Diagnostics System (QDS)
Number of subjects: 39
Study 35759721 — intervention group
Group type: COMPARATOR
Intervention: Measuring Energy Expenditure in ECMO patients (MEEP)
Number of subjects: 39
Study 35759791 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training and workshops for care teams in interprofessional shared decision-making (1.5-hour tutorial + 3.5-hour workshop)
Number of subjects: 311
Study 35759791 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training and workshops for care teams in interprofessional shared decision-making
Number of subjects: 311
Study 35759791 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of the decision guide
Number of subjects: 311
Study 35760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal mammary artery (LIMA) graft
Number of subjects: 1068
Study 35760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 1068
Study 35760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein graft
Number of subjects: 1068
Study 35760616 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal mammary artery (RIMA) graft
Number of subjects: 1068
Study 35760616 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RIMA to radial artery and saphenous vein grafts
Number of subjects: 1068
Study 35760819 — intervention group
Group type: EXPERIMENTAL
Intervention: ARISES smartphone-based platform with deep learning algorithm
Number of subjects: 12
Study 35760819 — intervention group
Group type: COMPARATOR
Intervention: Use of wristband data
Number of subjects: 12
Study 35760920 — intervention group
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula (RIF)
Number of subjects: 0
Study 35760920 — intervention group
Group type: COMPARATOR
Intervention: Arsenic trioxide
Number of subjects: 0
Study 35760939 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (various vaccines including Gam-COVID-Vac, ChAdOx1 nCoV-19, BBIBP-CorV)
Number of subjects: 1234
Study 35760939 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 1234
Study 35761234 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC budesonide/formoterol via the Elpenhaler device
Number of subjects: 716
Study 35761306 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 10
Study 35761306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 10
Study 35761306 — intervention group
Group type: COMPARATOR
Intervention: Both PDT and CBT
Number of subjects: 10
Study 35761404 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 71
Study 35762292 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block use
Number of subjects: 2678
Study 35762292 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (C3 cluster)
Number of subjects: 2678
Study 35762292 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 2678
Study 35762796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP-PI-HBr)
Number of subjects: 0
Study 35762834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5)
Number of subjects: 212
Study 35762834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 212
Study 35762834 — intervention group
Group type: COMPARATOR
Intervention: Control group (remdesivir only)
Number of subjects: 212
Study 35762890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with yttrium 90, details on dosage and duration not available.
Number of subjects: 0
Study 35762891 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon 129
Number of subjects: 40
Study 35762891 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 participants)
Number of subjects: 40
Study 35762891 — intervention group
Group type: EXPERIMENTAL
Intervention: PACS group (34 participants)
Number of subjects: 40
Study 35762935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health service provider-presented video outreach program
Number of subjects: 217
Study 35762935 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-presented video outreach program
Number of subjects: 217
Study 35762935 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison group
Number of subjects: 217
Study 35763113 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 155
Study 35763235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) placement
Number of subjects: 56
Study 35763342 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche HD Digital Monitoring Platform
Number of subjects: 219
Study 35763351 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patches (200 µg/day) for 3 weeks postpartum
Number of subjects: 220
Study 35763351 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches for 3 weeks postpartum
Number of subjects: 220
Study 35763600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free cardiorespiratory fitness (FF-V̇O 2max)
Number of subjects: 121
Study 35763600 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess adiposity (visceral adipose tissue [VAT], body mass index [BMI], whole-body percent fat [WB%FAT])
Number of subjects: 121
Study 35763667 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for SERs after 3 chemotherapy cycles.
Number of subjects: 135
Study 35763667 — intervention group
Group type: COMPARATOR
Intervention: No involved-field radiotherapy (IFRT) for SERs after 3 chemotherapy cycles.
Number of subjects: 135
Study 35763667 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for RERs after 3 chemotherapy cycles.
Number of subjects: 135
Study 35763667 — intervention group
Group type: COMPARATOR
Intervention: No involved-field radiotherapy (IFRT) for RERs after 3 chemotherapy cycles.
Number of subjects: 135
Study 35763768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based evaluations
Number of subjects: 300
Study 35763768 — intervention group
Group type: COMPARATOR
Intervention: More expensive techniques (magnetic resonance imaging, positron emission tomography, computed tomography)
Number of subjects: 300
Study 35763887 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cerebral palsy group
Number of subjects: 20
Study 35763887 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children group
Number of subjects: 20
Study 35764393 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of mRNA vaccine administered within 6 months after the second dose
Number of subjects: 108
Study 35764393 — intervention group
Group type: COMPARATOR
Intervention: Two doses of mRNA vaccine
Number of subjects: 108
Study 35764393 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of mRNA vaccine
Number of subjects: 108
Study 35764593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive strategies
Number of subjects: 4936
Study 35764593 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality traits (especially neuroticism)
Number of subjects: 4936
Study 35764593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive beliefs and strategies
Number of subjects: 4936
Study 35764593 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models based on personality traits versus metacognitions
Number of subjects: 4936
Study 35764638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral-transduced autologous hematopoietic stem cells following busulfan (6 mg/kg total) conditioning
Number of subjects: 19
Study 35764637 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of BNT162b2 (BB)
Number of subjects: 239
Study 35764637 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of CoronaVac (CC)
Number of subjects: 239
Study 35764637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of BNT162b2 (B)
Number of subjects: 239
Study 35764637 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (CC)
Number of subjects: 239
Study 35764637 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (BB)
Number of subjects: 239
Study 35764637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (BNT162b2 and CoronaVac)
Number of subjects: 239
Study 35764773 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (total daily dose of 20-400 mg)
Number of subjects: 353
Study 35764773 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (80 mg total daily dose as 40 mg twice daily or 80 mg once daily)
Number of subjects: 353
Study 35764773 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib (not specified dosage)
Number of subjects: 353
Study 35764796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized clinical trial (DCT) with oral anticoagulation adherence (OACA)
Number of subjects: 100
Study 35764796 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized clinical trial (DCT) with low baseline OACA (<90%)
Number of subjects: 100
Study 35764796 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement metrics from DCT
Number of subjects: 100
Study 35764796 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback from DCT
Number of subjects: 100
Study 35764995 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey during child's induction (T1)
Number of subjects: 15
Study 35764995 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey during maintenance therapy (T2)
Number of subjects: 15
Study 35764995 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey near treatment completion (T3)
Number of subjects: 15
Study 35764995 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional semi-structured interview
Number of subjects: 15
Study 35764995 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual survey about institution resources
Number of subjects: 15
Study 35765007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual block HER2 assessment
Number of subjects: 3806
Study 35765055 — intervention group
Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec (VN)
Number of subjects: 0
Study 35765055 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 35765145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of donor-derived cell-free DNA (dd-cfDNA) fraction and quantity
Number of subjects: 367
Study 35765145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-variable system (dd-cfDNA fraction and quantity)
Number of subjects: 367
Study 35765145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-threshold algorithm for molecular diagnoses
Number of subjects: 367
Study 35765145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-threshold algorithm for histology diagnoses
Number of subjects: 367
Study 35765711 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) for striatal blood-brain barrier (BBB) opening
Number of subjects: 7
Study 35766394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional watch and wait (W&W) after neoadjuvant chemoradiotherapy plus consolidation CAPEOX
Number of subjects: 64
Study 35766641 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP
Number of subjects: 404
Study 35766641 — intervention group
Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 404
Study 35766976 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 glucose response profile
Number of subjects: 2378
Study 35766976 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 glucose response profile
Number of subjects: 2378
Study 35766976 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 4 glucose response profile
Number of subjects: 2378
Study 35766976 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 2378
Study 35766976 — intervention group
Group type: EXPERIMENTAL
Intervention: β-cell glucose sensitivity
Number of subjects: 2378
Study 35767123 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 708
Study 35767123 — intervention group
Group type: COMPARATOR
Intervention: No inhaled corticosteroids (ICS) treatment
Number of subjects: 708
Study 35767182 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg per day)
Number of subjects: 5
Study 35767182 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with radioactive iodine (RAI) therapy
Number of subjects: 5
Study 35767205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib (10-200 mg)
Number of subjects: 193
Study 35767205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib (150 mg)
Number of subjects: 193
Study 35767205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Number of subjects: 193
Study 35767233 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous monitoring of oxygen (tcpO2)
Number of subjects: 10
Study 35767233 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous monitoring of carbon dioxide (tcpCO2)
Number of subjects: 10
Study 35767435 — intervention group
Group type: EXPERIMENTAL
Intervention: Early spontaneous breathing during invasive mechanical ventilation (IMV)
Number of subjects: 0
Study 35767435 — intervention group
Group type: COMPARATOR
Intervention: Ventilation strategies avoiding spontaneous breathing (e.g. using NMBA or deep sedation)
Number of subjects: 0
Study 35767439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic virus DNX-2401 infusion followed by radiotherapy
Number of subjects: 12
Study 35768023 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiation therapy)
Number of subjects: 8
Study 35768023 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-STAR
Number of subjects: 8
Study 35768023 — intervention group
Group type: COMPARATOR
Intervention: nonadapted CT-guided stereotactic body radiation therapy (SBRT)
Number of subjects: 8
Study 35768164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-transduced T-cell product (TBI-1301) with a dose of 5×10
Number of subjects: 0
Study 35768164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-transduced T-cell product (TBI-1301)
Number of subjects: 0
Study 35768575 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Body Composition (VBC) using smartphone camera
Number of subjects: 134